Renzapride Accelerates Colonic Transit in IBS-C Patients

Published Online: Wednesday, December 1, 2004

The pathophysiology of irritable bowel syndrome (IBS) is thought to be multifactorial, and physical and psychosocial factors may contribute to overall symptom presentation. Therapies that target these contributing factors have been developed.

Renzapride is a serotonin type 4 receptor agonist/type 3 receptor antagonist. The effect of this agent on colonic transit (CT) in patients with IBS with constipation (IBS-C; n = 48, of whom 46 were women) was examined. The findings of this study were published in the October 2004 issue of Clinical Gastroenterology and Hepatology.

Results demonstrated a linear dose response to renzapride for CT and ascending colon emptying, but not for gastric emptying or small bowel transit. The median ascending colon half-time transit was 5.0 hours in patients treated with 4 mg renzapride (n = 12), compared with 17.5 hours in those in the placebo group (n = 12). Improved bowel function scores (ie, stool form, ease of passage) were significantly (P < .05) associated with accelerated CT. The authors concluded that renzapride causes clinically significant CT acceleration, which is associated with bowel function improvement in women with IBS-C.



Latest Articles
This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings and more.
Chronic kidney disease incidence has grown faster than many of its common comorbidities such as diabetes and hypertension, and medications may be an underappreciated driver of this growth.
President Barack Obama’s fiscal year 2017 budget proposal calls for an additional $1.1 billion to combat the nation’s spiraling opioid epidemic.
Baxter International is voluntarily recalling intravenous solution due to leaking containers and the potential for particulate matter.
Latest Issues
$auto_registration$
VSEO N/A